Fulcrum Therapeutics Stock Performance
| FULC Stock | USD 3.96 0.02 0.50% |
On a scale of 0 to 100, Fulcrum Therapeutics holds a performance score of 6. The firm shows a Beta (market volatility) of 0.38, which means possible diversification benefits within a given portfolio. As returns on the market increase, Fulcrum Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Fulcrum Therapeutics is expected to be smaller as well. Please check Fulcrum Therapeutics' jensen alpha, potential upside, accumulation distribution, as well as the relationship between the treynor ratio and expected short fall , to make a quick decision on whether Fulcrum Therapeutics' price patterns will revert.
Risk-Adjusted Performance
6 of 100
Weak | Strong |
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in Fulcrum Therapeutics are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. In spite of rather uncertain essential indicators, Fulcrum Therapeutics exhibited solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (0.50) | Five Day Return (5.71) | Year To Date Return (18.18) | Ten Year Return (70.67) | All Time Return (70.67) |
1 | Fulcrum Therapeutics to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, November 13, 2024 at 800 a.m. ET | 11/06/2024 |
2 | Insider Trading | 11/12/2024 |
3 | Fulcrum Therapeutics GAAP EPS of -0.35 beats by 0.05 | 11/13/2024 |
4 | Fulcrum Therapeutics Third Quarter 2024 Earnings US0.35 loss per share | 11/15/2024 |
5 | Fulcrum Therapeutics stock hits 52-week low at 2.87 - Investing.com | 11/19/2024 |
6 | Disposition of 6766 shares by Gould Robert J of Fulcrum Therapeutics at 15.0 subject to Rule 16b-3 | 12/06/2024 |
7 | Fulcrum Therapeutics Insider Purchases Yet To Pay Off Regardless Of Recent Strength | 12/12/2024 |
8 | Theres Reason For Concern Over Fulcrum Therapeutics, Inc.s Massive 34 percent Price Jump | 12/23/2024 |
9 | Fulcrum Therapeutics Advances Pociredir for Sickle Cell Disease - TipRanks | 01/13/2025 |
| Begin Period Cash Flow | 36.2 M | |
| Free Cash Flow | -91.5 M |
Fulcrum |
Fulcrum Therapeutics Relative Risk vs. Return Landscape
If you would invest 339.00 in Fulcrum Therapeutics on October 22, 2024 and sell it today you would earn a total of 57.00 from holding Fulcrum Therapeutics or generate 16.81% return on investment over 90 days. Fulcrum Therapeutics is currently generating 0.3491% in daily expected returns and assumes 4.496% risk (volatility on return distribution) over the 90 days horizon. In different words, 40% of stocks are less volatile than Fulcrum, and 94% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Fulcrum Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Fulcrum Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Fulcrum Therapeutics, and traders can use it to determine the average amount a Fulcrum Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0777
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | FULC | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.5 actual daily | 40 60% of assets are more volatile |
Expected Return
| 0.35 actual daily | 6 94% of assets have higher returns |
Risk-Adjusted Return
| 0.08 actual daily | 6 94% of assets perform better |
Based on monthly moving average Fulcrum Therapeutics is performing at about 6% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Fulcrum Therapeutics by adding it to a well-diversified portfolio.
Fulcrum Therapeutics Fundamentals Growth
Fulcrum Stock prices reflect investors' perceptions of the future prospects and financial health of Fulcrum Therapeutics, and Fulcrum Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Fulcrum Stock performance.
| Return On Equity | -0.0737 | ||||
| Return On Asset | -0.0689 | ||||
| Profit Margin | (0.25) % | ||||
| Operating Margin | 0.66 % | ||||
| Current Valuation | (34.49 M) | ||||
| Shares Outstanding | 53.94 M | ||||
| Price To Earning | (1.99) X | ||||
| Price To Book | 0.83 X | ||||
| Price To Sales | 2.62 X | ||||
| Revenue | 2.81 M | ||||
| Gross Profit | 7.36 M | ||||
| EBITDA | (108.49 M) | ||||
| Net Income | (97.33 M) | ||||
| Cash And Equivalents | 221.79 M | ||||
| Cash Per Share | 4.26 X | ||||
| Total Debt | 10.82 M | ||||
| Debt To Equity | 0.06 % | ||||
| Current Ratio | 15.49 X | ||||
| Book Value Per Share | 3.80 X | ||||
| Cash Flow From Operations | (90.97 M) | ||||
| Earnings Per Share | (0.29) X | ||||
| Market Capitalization | 213.6 M | ||||
| Total Asset | 257.69 M | ||||
| Retained Earnings | (509.67 M) | ||||
| Working Capital | 228.52 M | ||||
| Current Asset | 22.54 M | ||||
| Current Liabilities | 3.5 M | ||||
About Fulcrum Therapeutics Performance
By analyzing Fulcrum Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Fulcrum Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Fulcrum Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Fulcrum Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (148.15) | (140.74) | |
| Return On Tangible Assets | (0.34) | (0.36) | |
| Return On Capital Employed | (0.41) | (0.43) | |
| Return On Assets | (0.34) | (0.36) | |
| Return On Equity | (0.37) | (0.39) |
Things to note about Fulcrum Therapeutics performance evaluation
Checking the ongoing alerts about Fulcrum Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Fulcrum Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Fulcrum Therapeutics had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 2.81 M. Net Loss for the year was (97.33 M) with profit before overhead, payroll, taxes, and interest of 7.36 M. | |
| Fulcrum Therapeutics currently holds about 221.79 M in cash with (90.97 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.26, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Fulcrum Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 90.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Fulcrum Therapeutics Advances Pociredir for Sickle Cell Disease - TipRanks |
- Analyzing Fulcrum Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Fulcrum Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Fulcrum Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Fulcrum Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Fulcrum Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Fulcrum Therapeutics' stock. These opinions can provide insight into Fulcrum Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Fulcrum Stock analysis
When running Fulcrum Therapeutics' price analysis, check to measure Fulcrum Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fulcrum Therapeutics is operating at the current time. Most of Fulcrum Therapeutics' value examination focuses on studying past and present price action to predict the probability of Fulcrum Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fulcrum Therapeutics' price. Additionally, you may evaluate how the addition of Fulcrum Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Transaction History View history of all your transactions and understand their impact on performance | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm |